1 |
<p align="left"><font size="4" color="#FF9933"><b><font color="#000000" size="3">Development |
2 |
of NCE`s</font></b></font></p> |
3 |
<table width="90%" border="0" cellspacing="0" cellpadding="0" align="center"> |
4 |
<tr> |
5 |
<td height="10" width="19%"> |
6 |
<div align="center"><b>PROJECT</b></div> |
7 |
</td> |
8 |
<td height="10" width="26%"> |
9 |
<div align="center"><b>INDICATION</b></div> |
10 |
</td> |
11 |
<td height="10" width="24%"> |
12 |
<div align="center"><b>STATUS</b></div> |
13 |
</td> |
14 |
<td height="10" width="31%"> |
15 |
<div align="center"><b>MARKET POTENTIAL </b></div> |
16 |
</td> |
17 |
</tr> |
18 |
</table> |
19 |
<table width="90%" border="1" cellspacing="0" cellpadding="0" align="center"> |
20 |
<tr> |
21 |
<td width="19%"> |
22 |
<div align="center">PLD - 116</div> |
23 |
</td> |
24 |
<td width="26%"> |
25 |
<div align="center">Inflammatory Bowel Disease (IBD)</div> |
26 |
</td> |
27 |
<td width="24%"> |
28 |
<div align="center">Preclinical Development</div> |
29 |
</td> |
30 |
<td width="31%"> |
31 |
<div align="center">US$ 600 m. to US$ 1bn</div> |
32 |
</td> |
33 |
</tr> |
34 |
<tr> |
35 |
<td width="19%"> |
36 |
<div align="center">PLD - 117</div> |
37 |
</td> |
38 |
<td width="26%"> |
39 |
<div align="center">Oncology<br> |
40 |
Hematology</div> |
41 |
</td> |
42 |
<td width="24%"> |
43 |
<div align="center">Preclinical Development</div> |
44 |
</td> |
45 |
<td width="31%"> |
46 |
<div align="center">US$ 600-900 m.</div> |
47 |
</td> |
48 |
</tr> |
49 |
<tr> |
50 |
<td width="19%"> |
51 |
<div align="center">PLD - 118</div> |
52 |
</td> |
53 |
<td width="26%"> |
54 |
<div align="center">Anti-fungal</div> |
55 |
</td> |
56 |
<td width="24%"> |
57 |
<div align="center">Preclinical Development</div> |
58 |
</td> |
59 |
<td width="31%"> |
60 |
<div align="center">US$ 600-800 m.</div> |
61 |
</td> |
62 |
</tr> |
63 |
<tr> |
64 |
<td width="19%"> |
65 |
<div align="center">PLR - 1</div> |
66 |
</td> |
67 |
<td width="26%"> |
68 |
<div align="center">Anti-infective</div> |
69 |
</td> |
70 |
<td width="24%"> |
71 |
<div align="center">Discovery</div> |
72 |
</td> |
73 |
<td width="31%"> |
74 |
<div align="center">~ US$ 1 bn</div> |
75 |
</td> |
76 |
</tr> |
77 |
<tr> |
78 |
<td width="19%"> |
79 |
<div align="center">PLR - 13</div> |
80 |
</td> |
81 |
<td width="26%"> |
82 |
<div align="center">Inflammation<br> |
83 |
Asthma</div> |
84 |
</td> |
85 |
<td width="24%"> |
86 |
<div align="center">Discovery</div> |
87 |
</td> |
88 |
<td width="31%"> |
89 |
<div align="center">~ US$ 500 m.</div> |
90 |
</td> |
91 |
</tr> |
92 |
<tr> |
93 |
<td width="19%"> |
94 |
<div align="center">PLR - 9</div> |
95 |
</td> |
96 |
<td width="26%"> |
97 |
<div align="center">Anti-infective</div> |
98 |
</td> |
99 |
<td width="24%"> |
100 |
<div align="center">Discovery</div> |
101 |
</td> |
102 |
<td width="31%"> |
103 |
<div align="center">~ US$ 1 bn</div> |
104 |
</td> |
105 |
</tr> |
106 |
<tr> |
107 |
<td width="19%"> |
108 |
<div align="center">PLR - 14</div> |
109 |
</td> |
110 |
<td width="26%"> |
111 |
<div align="center">Inflammation<br> |
112 |
RA, IBD</div> |
113 |
</td> |
114 |
<td width="24%"> |
115 |
<div align="center">Discovery</div> |
116 |
</td> |
117 |
<td width="31%"> |
118 |
<div align="center">~ US$ 1 bn </div> |
119 |
</td> |
120 |
</tr> |
121 |
</table> |
122 |
<table width="100%" border="0" cellspacing="3" cellpadding="0"> |
123 |
<tr> |
124 |
<td> |
125 |
<hr size="1" width="100%"> |
126 |
</td> |
127 |
</tr> |
128 |
</table> |
129 |
<p><b>Development of Generics</b></p> |
130 |
<table width="90%" align="center" border="0" cellspacing="0" cellpadding="0"> |
131 |
<tr> |
132 |
<td width="25%" height="35"> |
133 |
<div align="center"><b>GENERIC PRODUCT</b></div> |
134 |
</td> |
135 |
<td width="23%" height="35"> |
136 |
<div align="center"><b>FIRST REGISTRATION EXPECTED</b> </div> |
137 |
</td> |
138 |
<td width="25%" height="35"> |
139 |
<div align="center"><b>GENERIC PRODUCT</b></div> |
140 |
</td> |
141 |
<td width="27%" height="35"> |
142 |
<div align="center"><b>FIRST REGISTRATION EXPECTED</b></div> |
143 |
</td> |
144 |
</tr> |
145 |
<tr> |
146 |
<td colspan="4"> |
147 |
<table width="100%" border="1" cellspacing="0" cellpadding="0"> |
148 |
<tr> |
149 |
<td width="25%">Simvastatin</td> |
150 |
<td width="23%"> |
151 |
<div align="center">2001</div> |
152 |
</td> |
153 |
<td width="25%">Losartan</td> |
154 |
<td width="27%"> |
155 |
<div align="center">2002</div> |
156 |
</td> |
157 |
</tr> |
158 |
<tr> |
159 |
<td width="25%">Loratadin</td> |
160 |
<td width="23%"> |
161 |
<div align="center">2001</div> |
162 |
</td> |
163 |
<td width="25%">Carvedilol</td> |
164 |
<td width="27%"> |
165 |
<div align="center">2002</div> |
166 |
</td> |
167 |
</tr> |
168 |
<tr> |
169 |
<td width="25%">Erythropoietin</td> |
170 |
<td width="23%"> |
171 |
<div align="center">2001</div> |
172 |
</td> |
173 |
<td width="25%">Bisoprolol</td> |
174 |
<td width="27%"> |
175 |
<div align="center">2003</div> |
176 |
</td> |
177 |
</tr> |
178 |
<tr> |
179 |
<td width="25%">Warfarin</td> |
180 |
<td width="23%"> |
181 |
<div align="center">2001</div> |
182 |
</td> |
183 |
<td width="25%">Losartan+HCTZ</td> |
184 |
<td width="27%"> |
185 |
<div align="center">2003</div> |
186 |
</td> |
187 |
</tr> |
188 |
<tr> |
189 |
<td width="25%">Diklofenac</td> |
190 |
<td width="23%"> |
191 |
<div align="center">2001</div> |
192 |
</td> |
193 |
<td width="25%">Clarithromycin</td> |
194 |
<td width="27%"> |
195 |
<div align="center">2003</div> |
196 |
</td> |
197 |
</tr> |
198 |
<tr> |
199 |
<td width="25%">Ca folinat</td> |
200 |
<td width="23%"> |
201 |
<div align="center">2001</div> |
202 |
</td> |
203 |
<td width="25%">Venlafaxine</td> |
204 |
<td width="27%"> |
205 |
<div align="center">2003</div> |
206 |
</td> |
207 |
</tr> |
208 |
<tr> |
209 |
<td width="25%">Ondansetron</td> |
210 |
<td width="23%"> |
211 |
<div align="center">2002</div> |
212 |
</td> |
213 |
<td width="25%">Interferon alpha</td> |
214 |
<td width="27%"> |
215 |
<div align="center">2003</div> |
216 |
</td> |
217 |
</tr> |
218 |
<tr> |
219 |
<td width="25%">Torasemid</td> |
220 |
<td width="23%"> |
221 |
<div align="center">2002</div> |
222 |
</td> |
223 |
<td width="25%">Paroxetin</td> |
224 |
<td width="27%"> |
225 |
<div align="center">2003</div> |
226 |
</td> |
227 |
</tr> |
228 |
<tr> |
229 |
<td width="25%">Amlodipin</td> |
230 |
<td width="23%"> |
231 |
<div align="center">2002</div> |
232 |
</td> |
233 |
<td width="25%">HGH</td> |
234 |
<td width="27%"> |
235 |
<div align="center">2003</div> |
236 |
</td> |
237 |
</tr> |
238 |
<tr> |
239 |
<td width="25%">Risperidone</td> |
240 |
<td width="23%"> |
241 |
<div align="center">2002</div> |
242 |
</td> |
243 |
<td width="25%">Meloxicam</td> |
244 |
<td width="27%"> |
245 |
<div align="center">2003</div> |
246 |
</td> |
247 |
</tr> |
248 |
<tr> |
249 |
<td width="25%">Alendronate</td> |
250 |
<td width="23%"> |
251 |
<div align="center">2002</div> |
252 |
</td> |
253 |
<td width="25%">Interferon beta</td> |
254 |
<td width="27%"> |
255 |
<div align="center">2004</div> |
256 |
</td> |
257 |
</tr> |
258 |
<tr> |
259 |
<td width="25%">Ciprofloxacin</td> |
260 |
<td width="23%"> |
261 |
<div align="center">2002</div> |
262 |
</td> |
263 |
<td width="25%">Indapamide</td> |
264 |
<td width="27%"> |
265 |
<div align="center">2004</div> |
266 |
</td> |
267 |
</tr> |
268 |
<tr> |
269 |
<td width="25%">Mesalazin</td> |
270 |
<td width="23%"> |
271 |
<div align="center">2002</div> |
272 |
</td> |
273 |
<td width="25%">Cytostatics (9)</td> |
274 |
<td width="27%"> |
275 |
<div align="center">2001-2003</div> |
276 |
</td> |
277 |
</tr> |
278 |
<tr> |
279 |
<td width="25%">G-CSF </td> |
280 |
<td width="23%"> |
281 |
<div align="center">2002</div> |
282 |
</td> |
283 |
<td width="25%">OTC products (9)</td> |
284 |
<td width="27%"> |
285 |
<div align="center">2001-2003</div> |
286 |
</td> |
287 |
</tr> |
288 |
</table> |
289 |
</td> |
290 |
</tr> |
291 |
</table> |